Clinical trials: Diabetic Macular Edema
Macular Edema
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator.
- Trial name
- NCT04976777
- Testing
- Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbbVie
Retinal Vasculitis
A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
This study will describe and estimate the incidence of RV events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea® 2mg) therapy in US clinical practice.
- Trial name
- NCT06769412
- Testing
- aflibercept 2 mg
- Where
- United States
- Volunteers
- 550,000 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Macular Edema
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
The primary objective of the study was to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI) in improving best corrected visual acuity (BCVA) in participants…
- Trial name
- RUBY (NCT02712008)
- Testing
- REGN910-3, Intravitreal Aflibercept Injection (IAI)
- Where
- 51 sites in United States
- Volunteers
- 302 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Macular Edema, Diabetic Retinopathy
Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
The purpose of this study is to determine the safety and tolerability of MS-R001 at escalating doses in patients with diabetic macular edema secondary to diabetic retinopathy
- Trial name
- NCT00401115
- Testing
- MS-R001 (rapamycin)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Santen Inc.
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR [Part 1] and during an 8-week dosing period…
- Conditions
- Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema
- Trial name
- NCT06599684
- Testing
- INV-102
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Invirsa, Inc.
Diabetic Macular Edema
Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)
A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept
- Trial name
- VERONA (NCT06099184)
- Testing
- EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Anesthesia, Local, Intravitreal Injection
Long Term Safety of Cooling Anesthesia for Intravitreal Injection
The purpose of this clinical study is to evaluate the long term safety and efficacy of cooling anesthesia application to the eye as anesthesia for intravitreal injection using a novel cooling anesthesia device.
- Conditions
- Anesthesia, Local, Intravitreal Injection, Macular Edema, Macular Degeneration
- Trial name
- COOL-2 (NCT03956797)
- Testing
- Recens Cooling Anesthesia Device
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Recens Medical, Inc.
Diabetic Macular Edema
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
- Trial name
- NCT03927690
- Testing
- LKA651, Lucentis
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema (DME)
A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
The purpose of this study is to learn about the effects of BGE-102 on change in vision in participants with center-involved diabetic macular edema (CI-DME).
- Trial name
- QUELL-DME (NCT07812090)
- Testing
- Oral BGE-102, Anti-VEGF
- Where
- 16 sites in United States
- Volunteers
- 180 people
- Sponsor
- BioAge Labs, Inc.
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema
Part A of the study is conducted to select the THR-149 dose level. Part B of the study is conducted to assess the efficacy and safety of the selected dose level compared to aflibercept, up to Month 3.
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- KALAHARI (NCT04527107)
- Testing
- THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3
- Where
- 78 sites in United States, Czechia and 6 more
- Volunteers
- 135 people
- Sponsor
- Oxurion
Macular Edema
A Study of Abicipar Pegol in Patients With Diabetic Macular Edema
This is a safety and efficacy study of abicipar pegol in patients with diabetic macular edema.
- Trial name
- NCT02186119
- Testing
- abicipar pegol, ranibizumab
- Where
- 2 sites in United States
- Volunteers
- 151 people
- Sponsor
- Allergan
Diabetic Macular Edema
Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)
The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Diabetic Macular Edema (DME).
- Trial name
- NCT02914613
- Testing
- SF0166 Topical Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 44 people
- Sponsor
- OcuTerra Therapeutics, Inc.
Diabetic Macular Edema (DME)
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema…
- Trial name
- BAROLO (NCT06957080)
- Testing
- Remigromig, Ranibizumab
- Where
- 164 sites in United States, Argentina and 4 more
- Volunteers
- 1,054 people
- Sponsor
- EyeBiotech Ltd.
Diabetic Macular Edema, DME
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
- Conditions
- Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- Trial name
- DME (NCT07449936)
- Testing
- EYP-1901, Aflibercept (2.0 mg)
- Where
- 73 sites in United States, Germany and 3 more
- Volunteers
- 240 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Diabetic Macular Edema
The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)
This phase 2a trial is a randomized, open-label, parallel-group study in approximately 60 patients with DME to evaluate the efficacy and safety of CU06-1004 orally administered once daily for 12 weeks.
- Trial name
- NCT05573100
- Testing
- CU06-1004
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 67 people
- Sponsor
- Curacle Co., Ltd.
Diabetic Retinopathy, Macular Edema
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME.
- Trial name
- NCT07705555
- Testing
- MK-8748, Aflibercept
- Where
- 35 sites in United States, Argentina and 2 more
- Volunteers
- 960 people
- Sponsor
- Merck Sharp & Dohme LLC
Visual Impairment Due to Diabetic Macular Edema
Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of the study is to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF protein levels in DME patients in a detailed time course.
- Trial name
- TIDE DME (NCT02258009)
- Testing
- Ranibizumab, Aflibercept
- Where
- Germany
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
The Study of Drug 601 in Patients With Diabetic Macular Edema (DME)
Observe the safety and tolerability of the single and multiple doses of 601 in DME patients; study the pharmacokinetic characteristics of single and multiple doses of 601, Observe the Preliminary efficacy of 601 multiple…
- Trial name
- NCT04151407
- Testing
- Drug 601
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Visual Impairment Due to Diabetic Macular Edema
24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.
The purpose of the study is to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF levels in DME patients in a detailed time course.
- Trial name
- TIDE DME (NCT02878681)
- Testing
- Ranibizumab, Aflibercept
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Study of Two Multiple Intravitreal Doses of BAT5906 for Safety and Efficacy in Patients With Diabetic Macular Edema
This study is a multi-center, open, multiple-dose phase Ib/IIa clinical study evaluating the efficacy and safety of BAT5906 injection in patients with diabetic macular edema.
- Trial name
- NCT04772105
- Testing
- 2.5mg of BAT5906, 4.0mg of BAT5906
- Where
- 19 sites in China
- Volunteers
- 60 people
- Sponsor
- Bio-Thera Solutions